Mutant LRRK2 in lymphocytes regulates neurodegeneration via IL-6 in an inflammatory model of Parkinson’s disease

被引:0
|
作者
Elena Kozina
Matthew Byrne
Richard Jay Smeyne
机构
[1] Thomas Jefferson University,Department of Neurosciences, Jefferson Hospital for Neuroscience
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Mutations in a number of genes contribute to development of Parkinson’s disease (PD), including several within the LRRK2 gene. However, little is known about the signals that underlie LRRK2-mediated neuronal loss. One clue resides in the finding that the neurodegenerative cascades emanate from signals arising from the peripheral immune system. Here, using two chimeric mouse models, we demonstrate that: 1) the replacement of mutant LRRK2 with wt form of the protein in T- and B-lymphocytes diminishes LPS-mediated inflammation and rescues the SNpc DA neuron loss in the mutant LRRK2 brain; 2) the presence of G2019S or R1441G LRRK2 mutation in lymphocytes alone is sufficient for LPS-induced DA neuron loss in the genotypically wt brain; and 3) neutralization of peripheral IL-6 overproduction prevents the SNpc DA neuron loss in LPS-treated mutant LRRK2 mice. These results represent a major paradigm shift in our understanding of PD pathogenesis and suggest that immune dysfunction in some forms of familial PD may have primacy over the CNS as the initiating site of the disorder.
引用
收藏
相关论文
共 50 条
  • [21] Blocking IL-6 signaling prevents astrocyteinduced neurodegeneration in an iPSCbased model of Parkinson's disease
    Pons-Espinal, Meritxell
    Blasco-Agell, Lucas
    Fernandez-Carasa, Irene
    Andres-Benito, Pol
    di Domenico, Angelique
    Richaud-Patin, Yvonne
    Baruffi, Valentina
    Marruecos, Laura
    Espinosa, Lluis
    Garrido, Alicia
    Tolosa, Eduardo
    Edel, Michael J.
    Otero, Manel Juan
    Mosquera, Jose Luis
    Ferrer, Isidre
    Raya, Angel
    Consiglio, Antonella
    JCI INSIGHT, 2024, 9 (03)
  • [22] Hypercholinergic activity in LRRK2 Parkinson's disease
    Bohnen, Nicolaas I.
    Albin, Roger L.
    LANCET NEUROLOGY, 2018, 17 (04): : 290 - 291
  • [23] Genetics of Parkinson's disease: LRRK2 on the rise
    Brice, A
    BRAIN, 2005, 128 : 2760 - 2762
  • [24] Metabolomic analysis in LRRK2 Parkinson's disease
    Johansen, K. K.
    Matson, W.
    Beal, F.
    Aasly, J. O.
    Bogdanov, M.
    MOVEMENT DISORDERS, 2007, 22 : S187 - S187
  • [25] Inhibitors of LRRK2 as Treatment for Parkinson's Disease
    Abdel-Magid, Ahmed F.
    ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (09): : 701 - 702
  • [26] LRRK2 at the Crossroad of Aging and Parkinson's Disease
    Hur, Eun-Mi
    Lee, Byoung Dae
    GENES, 2021, 12 (04)
  • [27] Identification of LRRK2 mutations in Parkinson's disease
    Lewthwaite, A. J.
    Nicholl, D. J.
    Morrison, K. E.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2006, 77 (12): : 1397 - 1397
  • [28] Analysis of LRRK2 variants in Parkinson's disease
    Au, W. L.
    Ho, P.
    Zhao, Y.
    Tan, L. C. S.
    Tan, E. K.
    MOVEMENT DISORDERS, 2010, 25 (07) : S468 - S468
  • [29] LRRK2 is reduced in Parkinson’s disease gut
    Adrien de Guilhem de Lataillade
    Jérémy Verchere
    Thibauld Oullier
    Alice Prigent
    Tony Durand
    Carolina Pellegrini
    Michel Neunlist
    Thierry Baron
    Malvyne Rolli-Derkinderen
    Pascal Derkinderen
    Acta Neuropathologica, 2021, 142 : 601 - 603
  • [30] Mutations in LRRK2 as a cause of Parkinson's disease
    Giasson, Benoit I.
    Van Deerlin, Vivianna M.
    NEUROSIGNALS, 2008, 16 (01) : 99 - 105